SBIR-STTR Award

Clonogenic High Throughput Asssay for Screening Radiation Modulators
Award last edited on: 7/17/2018

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$297,604
Award Phase
1
Solicitation Topic Code
NCI
Principal Investigator
Barbara Frederick

Company Information

Suvica Inc

PO Box 3131
Boulder, CO 80307
   (303) 921-6680
   info@suvica.com
   www.suvica.com
Location: Single
Congr. District: 02
County: Boulder

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2017
Phase I Amount
$297,604
Clonogneic assays measure the ability of single cells to proliferate and form a colony This process approximates closely the regrowth and recurance of tumors after treatment with radiation or chemotherapy providing a ready assay to screen for drugs that block this process Yet clonogenic assays are laborintensive and too cumbersome for high throughout screening HTS of compound libraries Here we propose to develop a HTS system based on a clonogenic endpoint A close examination of the literature and our own work shows that all necessary components for an HTS with a clonogenic endpoints already exist through efforts in the industry and academia We will combine these and validate their utility by comparing with conventional clonogenic assays to produce an HTS system with defined and validated standared opeating procedures This system will be transferrable to other laboratories Potential commercial applications include screening compound libraries for hits with dose modification for radiation or chemotherapeutics The HTS system we propose to develop will allow us to identify new compounds with the potential to inhibit regrowth of tumors after treatment The HTS system will also allow us to rapidly test the efficacy of combining existing drugs or drugs with radiation thus identifying rational treatment combinations

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----